Frank S. Czerwiec - Concepedia

Author

Frank S. Czerwiec

Also Known As

Czerwiec, F.S., F Czerwiec, F S Czerwiec, F. Czerwiec, F. S. Czerwiec, F.S. Czerwiec, FRANK S. CZERWIEC, Frank Czerwiec, Frank S Czerwiec, Frank S. Czerwiec

Publications

7.7K

Citations

H-Index

Concepts

All Affiliations

Otsuka (United States)Pharmaceutical Product Development (United States)Mayo Clinic Tufts Medical Center University of Chicago

About

Frank S. Czerwiec is an author at Otsuka (United States) specializing in medicine, nephrology, and chronic kidney disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	17	1.4K
2	Cell Biology	2	2	94
3	Health Sciences	1	1	343
4	Social Sciences	1	1	62
5	Anesthesia	1	1	135

Frank S. Czerwiec

Publications

7.5K

Citations

H-Index

Page 1

	Year	Citations
Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease Vicente E. Torres, Arlene B. Chapman, Olivier Devuyst, New England Journal of Medicine	2012	1.5K
Tolvaptan, a Selective Oral Vasopressin V <sub>2</sub> -Receptor Antagonist, for Hyponatremia Robert W. Schrier, Mihai Gheorghiade, Tomás Berl, New England Journal of Medicine	2006	1.2K
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease Vicente E. Torres, Arlene B. Chapman, Olivier Devuyst, New England Journal of Medicine	2017	578
Vasopressin V <sub>2</sub> -Receptor Blockade With Tolvaptan in Patients With Chronic Heart Failure Mihai Gheorghiade, Imran Khan Niazi, John Ouyang, Circulation	2003	430
Oral Tolvaptan Is Safe and Effective in Chronic Hyponatremia Tomás Berl, Friederike Quittnat-Pelletier, Joseph G. Verbalis, Journal of the American Society of Nephrology HypertensionElectrolyte DisorderOral MedicinePharmacotherapyElectrolyte Disturbance	2010	343
Prevalence of autosomal dominant polycystic kidney disease in the European Union Cynthia Willey, Jaime D. Blais, Anthony K Hall, Nephrology Dialysis Transplantation	2016	237
Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion Joseph G. Verbalis, Suzanne Myers Adler, Robert W. Schrier, European Journal of Endocrinology	2011	189
Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database Paul B. Watkins, James H. Lewis, Neil Kaplowitz, Drug Safety	2015	187
Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial Vicente E. Torres, Arlene B. Chapman, Olivier Devuyst, Nephrology Dialysis Transplantation	2017	174
Tolvaptan in Autosomal Dominant Polycystic Kidney Disease Eiji Higashihara, Vicente E. Torres, Arlene B. Chapman, Clinical Journal of the American Society of Nephrology	2011	148

Page 1